Recombinant antibody fragments as autoantibody antagonists

Bibliography

• VAN NOORT JM, VAN SECHEL AC, BAJRAMOVIC JJ et al.: The small heat-shock protein a B-crystallin as candidate autoantigen in multiple sclerosis. Nature. (1995) 375:798–801.
   PubMed Web of Science ®Google Scholar
• MURARO P, KALBUS M, AFSHAR G, MCFARLAND H, MARTIN R:T cell response to 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) in multiple sclerosis patients.' Neuroinununoi (2002) 130:233.
   Google Scholar
• O'CONNOR KC, BAR-OR A, HAFLER DA: The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis.J. Clin. Inununol. (2001) 21:81–92.
   PubMed Web of Science ®Google Scholar
• MOORE FG, WOLFSON C: Human herpes virus 6 and multiple sclerosis. Acta Neurol Scand. (2002) 106:63–83.
   PubMed Web of Science ®Google Scholar
• THEIL DJ, TSUNODA I, RODRIGUEZ F, WHITTON JL, FUJINAMI RS: Viruses can silently prime for and trigger central nervous system autoimmune disease. Neurovirol. (2001) 7:220–227.
   PubMedGoogle Scholar
• AMOR S, O'NEILL JK, MORRIS MM et al.: Encephalitogenic epitopes of myelin basic protein, proteolipid protein and myelin oligodendrocyte protein for EAE induction in Biozzi ABH (H-2A±11) mice share an amino acid motif." Immunol. (1996) 156: 3000–3008.
   Google Scholar
• MORRIS-DOWNES MM, MCCORMACK K, BAKER D, SIVAPRASAD D, NATKUNARAJAH J, AMOR S: Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (IVIAG), oligodendrocyte-specific glycoprotein (OSP) and 2',3'-cyclic nucleotide T-phosphodiesterase (CNPase) in ABH and SJL mice. Neuroinonunoi (2002) 122:20–33.
   Google Scholar
• THOUA N, VAN NOORT JM, BAKER D et al.: Encephalitogenic and immunological potential of the stress protein aB-crystallin (peptide 1-16) in Biozzi ABH (H-2A±11-) mice. Neurainonunol. (2000) 104:47–57.
   PubMedGoogle Scholar
• MORRIS-DOWNES MM, SMITH PA, RUNDLE JL et al.: Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. Neuroimmund (2002) 125:114–124.
   PubMed Web of Science ®Google Scholar
• •This paper clearly demonstrates that monoclonal antibodies to MOG, but not other myelin antigens, exacerbate disease in mice and this is related to the increase in demyelination.
   Google Scholar
• STORCH MK, STEFFERL A, BREHM U et al.: Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathoi (1998) 8:681–694.
   PubMed Web of Science ®Google Scholar
• GENAIN CP, NGUYEN MH, LETVIN NL et al.: Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. Clin. Invest. (1995) 96:2966–2974.
   Google Scholar
• ••The paper demonstrates that antibodies to MOG are critical for development of demyelination in non-human primates, which is the model used to demonstrate proof of principle in the patent application.
   Google Scholar
• MCFARLAND HI, LOBITO AA, JOHNSON MM et al.: Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis.' Inununol. (1999) 162:2384–2390.
   Google Scholar
• GENAIN CP, CANNELLA B, HAUSER SL, RAINE CS: Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med (1999) 5:170–175.
   PubMed Web of Science ®Google Scholar
• IGLESIAS A, BAUER J, LITZENBURGER T, SCHUBART A, LININGTON C: T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia (2001) 36:220–234.
   PubMed Web of Science ®Google Scholar
• RAINE CS, CANNELLA B, HAUSER SL, GENAIN CP: Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. (1999) 46:144–160.
   PubMed Web of Science ®Google Scholar
• BREHM U, PIDDLESDEN SJ, GARDINIER MV, LININGTON C: Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). Neurainonunol. (1999) 97:9–15.
   PubMedGoogle Scholar
• SORENSEN PS: The effect on MRI of gammaglobulin treatment in relapsing multiple sclerosis. Malt. Scler. (2000) (Supp1.2) :S14–7.
   Google Scholar
• VON BUDINGEN HC, HAUSER SL, FUHRMANN A, NABAVI CB, LEE JI, GENAIN CP: Molecular characterization of antibody specificities against myelin/ oligodendrocyte glycoprotein in autoimmune demyelination. Proc. Nati Acad. Sri. USA (2002) 99:8207–8212.
   PubMedGoogle Scholar
• UCCELLI A, GIUNTI D, MAN CARDI G et al: Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. Ear: brununol. (2001) 31:474–479.
   PubMedGoogle Scholar
• BROK HP, UCCELLI A, KERLERO DE ROSBO N et al.: Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pM0G24-36 is presented by a monomorphic MHC class II molecule. brununol. (2000) 165:1093–1101.
   Google Scholar
• BUCHWALD B, AHANGARI R, VVEISHAUPT A, TOYKA KV: Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann. Neurol (2002) 51:673–680.
   PubMed Web of Science ®Google Scholar
• PAPANASTASIOU D, POULAS K, KOKLA A,TZARTOS SJ: Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor. Neuroinonunoi (2000) 104:124–132.
   Google Scholar
• EGG R, REINDL M, DEISENHAMMER F, LININGTON C, BERGER T: Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Malt. Scler (2001) 7:285–289.
   PubMed Web of Science ®Google Scholar
• HAASE CG, GUGGENMOS J, BREHM U et al: The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. Neuroimmund (2001) 114:220–225.
   PubMedGoogle Scholar
• MITSUNAGA Y, CIRIC B, VAN KEULEN V et al: Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB (2002) 16:1325–1327.
   PubMed Web of Science ®Google Scholar